« Return to News | R&D Trends

Tufts CSDD receives research grant from goBalto

Thursday, November 17, 2011 02:49 PM

San Francisco-based goBalto, a developer of new generation web-based clinical research solutions, is providing a research grant for the Tufts Center for the Study of Drug Development to benchmark the clinical trial initiation process. Currently there is virtually no industry data available on the typical process that companies follow and on the amount of time that this process takes.

Tufts CSDD, an independent, non-profit academic research group at Tufts University in Boston, routinely conducts benchmark studies of critical drug development functions and activities. For this study, 15 international biotechnology and pharmaceutical companies and CROs will provide data on their experiences initiating clinical trials.

“This study will map the steps and duration of the clinical trial initiation process," said Ken Getz, senior research fellow at Tufts CSDD, principal investigator on the project, and owner of CenterWatch. "We anticipate identifying critical insights that sponsors and CROs can use to accelerate their study start-up times and drive higher levels of efficiency and effectiveness in the process."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.